PBR Nachrichten

 

This comes just two weeks after its US Food and Drug Administration (FDA) approval. The approval is based on results from FIBRONEER-IPF, a Phase III trial in IPF The post Boehringer's Jascayd gains NMPA approval for idiopathic pulmonary fibrosis appeared first on Pharmaceutical Business review....

In preclinical and Phase I studies in healthy participants, PORT-77 demonstrated a substantial reduction of plasma protoporphyrin IX (PPIX) through rapid ABCG2 inhibition. This outcome has the potential The post Portal Therapeutics receives FDA orphan, fast track designations for PORT-77 appeared first on Pharmaceutical Business review....

Under this agreement, McKesson will act as an authorised distributor for the immunotherapy that has received approval from the US Food and Drug Administration (FDA) to treat adults The post Citius Oncology finalises McKesson deal for Lymphir distribution appeared first on Pharmaceutical Business review....

This partnership will utilise Tempus' de-identified multimodal database to guide the design of clinical trials. Under the multi-year agreement, Whitehawk will utilise Tempus' real-world dataset to focus on The post Tempus partners with Whitehawk on oncology research appeared first on Pharmaceutical Business review....

The inhaler administers three active ingredients through a single device, known as single inhaler triple therapy (SITT), which has already received approval in nearly 50 countries. It combines The post FDA accepts Chiesi triple combination inhaler application for asthma appeared first on Pharmaceutical Business review....

The collaboration aims to clarify the underlying mechanism of action of iQ-007. The results will assist in stratifying and identifying patients who may benefit from this astrocyte-targeted therapy, The post iQure, University of Padova collaborate to investigate iQ-007 mechanism appeared first on Pharmaceutical Business review....

The FDA has also approved BeOne's application to participate in Project Orbis, an initiative that offers a framework for concurrent submission and oncology products review among collaborating health The post US FDA grants BeOne's sonrotoclax breakthrough designation for MCL appeared first on Pharmaceutical Business review....

ADCE-D01 is an antibody-drug conjugate (ADC) designed to target the urokinase plasminogen activator receptor-associated protein (uPARAP). Preclinical data indicate that ADCE-D01 exhibits anti-tumour activity in mesenchymal tumour models, The post Adcendo receives FDA fast track status for ADCE-D01 to treat STS appeared first on Pharmaceutical Business review....

BAT2506 is a proposed biosimilar of golimumab, developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that specifically targets tumour necrosis factor alpha (TNF-α), a key pro-inflammatory The post Bio-Thera, Intas extend partnership for golimumab biosimilar appeared first on Pharmaceutical Business review....

The funding will facilitate the establishment of Nilo's laboratories in New York City, the growth of the team, and the advancement of preclinical programmes. Furthermore, the company has appointed The post Nilo Therapeutics raises $101m to develop neural circuit therapies appeared first on Pharmaceutical Business review....

The funds will be used to advance the late-stage clinical development of the company's leading candidate, inhaled AERO-007. This nebulised LABA/LAMA combination is being developed as a potential The post AeroRx secures $21m for nebulised COPD treatment development appeared first on Pharmaceutical Business review....

Orca-T is being assessed to treat hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML), and acute lymphoblastic leukaemia (ALL). The FDA has granted priority review, with The post FDA accepts priority review for Orca Bio's hematological malignancy therapy appeared first on Pharmaceutical Business review....

Currently, there are no approved treatments for CIAS, a key feature of the condition that significantly affects daily functioning and the quality of life for individuals living with The post FDA fast-tracks Alto Neuroscience's ALTO-101 for CIAS treatment appeared first on Pharmaceutical Business review....

The oral treatment was approved for use on those who continue to experience symptoms despite receiving H1 antihistamine therapy. Rhapsido is administered in pill form twice daily and The post FDA approves Novartis' Rhapsido for CSU treatment appeared first on Pharmaceutical Business review....

The companies will collaborate on the development of GLIX1 as a potential treatment for both newly diagnosed and recurrent GBM. This molecule functions by enhancing TET2 activity within The post BioLineRx partners with Hemispherian to advance brain cancer therapy appeared first on Pharmaceutical Business review....

The submission draws on findings from the TEMPO clinical development programme, which assessed the tolerability, efficacy, and safety of tavapadon in various populations with Parkinson's disease. This programme The post AbbVie files NDA with FDA for tavapadon to treat Parkinson's disease appeared first on Pharmaceutical Business review....

The approval applies to individuals with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla, administered as a monthly infusion, is already available in several The post Lilly secures EC approval for Kisunla to treat Alzheimer's disease appeared first on Pharmaceutical Business review....

The launch follows approval from the US Food and Drug Administration (FDA). Iron sucrose is a key treatment for iron deficiency anaemia, affecting around five million people in The post Sandoz launches generic iron sucrose injection in US market appeared first on Pharmaceutical Business review....

The drug is indicated for adults with mild cognitive impairment or mild dementia, who are non-carriers or heterozygotes of apolipoprotein E ε4 (ApoE ε4) with confirmed amyloid pathology. The post Leqembi approved in Australia to treat early Alzheimer's appeared first on Pharmaceutical Business review....

The total capital raised by the company now stands at $446m, following a $386m series A/A-1 financing announced in November 2024. The series B round was led by The post Avenzo Therapeutics secures $60m in series B funding for oncology therapies appeared first on Pharmaceutical Business review....